Phase 3 MG Clinical Trials
4 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–4 of 4 trials
Recruiting
Phase 3
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Glioblastoma, IDH-wildtypeMGMT-Methylated Glioblastoma
Vastra Gotaland Region200 enrolled20 locationsNCT06419946
Recruiting
Phase 3
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Generalized Myasthenia GravisgMG
Alexion Pharmaceuticals, Inc.12 enrolled13 locationsNCT06607627
Recruiting
Phase 3
Zilucoplan for Severe gMG Exacerbations
Generalized Myasthenia Gravis (gMG)
Miriam Freimer15 enrolled1 locationNCT07215949
Not Yet Recruiting
Phase 3
A multicenter, double-blind, randomized study to compare the efficacy and safety of the combination of 145mg fenofibrate and simvastatin with 40mg simvastatin monotherapy in patients with mixed dyslipidemia at risk of cardiovascular disease not adequately controlled by 40 mg simvastatin alone
Patients with mixed dyslipidemia with CHD or CHD risk equivalent or with multiple risk factor and a 10 year risk above or equal to 10% and with TG above 1.71mmol/l and LDL >2.58 or >3.36mmol/l according to risk after 6 weeks of treatment with 40mg simvastatin.
Fournier Laboratories Ireland400 enrolled1 locationACTRN12605000777695